|
Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Business Market Research
Energy Market Research
Financial Market Research
Pharmaceutical Market Research
Telecoms Market Research
|
Home > Market Research > Prescription Medicines > U.S. Markets for Addiction & Substance Abuse Treatment
This Report:
The U.S. market for substance abuse treatment and diagnosis increased slightly from $2.6 billion in 2007 to $2.7 billion in 2008. It should reach $3.1 billion in 2013, for a compound annual growth rate (CAGR) of 2.7%.
Pharmaceutical treatments have the largest share of the market, worth $2.4 billion in 2007 and $2.5 billion in 2008. This should reach $2.8 billion in 2013, for a CAGR of 2.3%.
Diagnostic testing is the second largest market segment, generating $216.0 million in 2007 and $230.0 million in 2008. This segment is expected to increase at a CAGR 5.9% to reach $307.0 million in 2013.
STUDY GOALS AND OBJECTIVES
This BCC Research report details the complicated world of substance abuse. The increased prevalence of substance abuse poses a threat to the health and welfare of many populations throughout the world. Recreational drugs play a major role in crime and corruption and are becoming a larger problem each year. Abuse of prescription drugs and alcohol places a heavy burden on health resources due to the subsequent medical problems. Breaking the substance abuse cycle is a difficult and tedious process. Pharmaceutical manufacturers have developed several products to assist in recovery from substance abuse. Those products are detailed in the report. Also discussed are the products to help employers, parents, social workers, and other groups and organizations detect for substance abuse.
The objectives of the study are to heighten the awareness of drug abuse and to identify preparations, tests, and important advancements in the drug abuse treatment arena. The study analyzes the new therapeutics and diagnostics for drug abuse treatment from a current standpoint as well as what is on the horizon. Manufacturers of pharmaceutical products have been reluctant to invest valuable time and resources into this market because of the issues facing the market. As a result, the problem of drug abuse continues to grow.
REASONS FOR DOING THE STUDY
This BCC study is presented to increase the awareness of substance abuse and identify pharmaceutical preparations that are used to treat addictions.
INTENDED AUDIENCE
Because of the evolving nature of this important area of medicine, executives of substance abuse pharmaceuticals must remain ever vigilant to the changing environment and strive to keep abreast of new and currently used modalities in all facets of substance abuse treatment
SCOPE OF REPORT
The study is designed to be a comprehensive business tool that provides an in-depth look at the world of substance abuse treatments and diagnostics. The geographic scope of the report is the United States. The report identifies the different drugs of addiction; gives a brief explanation of the drug; outlines the characteristics of the drug; cites complications of the drug; presents current diagnostic testing; outlines current treatments, market size, and market participants; and discusses new developments and research. The report describes the industry in detail, its relationship to the healthcare industry, its economic consequences, its participants, and its trends for the future.
The following areas are addressed in this report:
Stimulants
Tobacco
Amphetamines
Cocaine, Crack
Depressants
Sedatives and Hypnotics
Alcohol
Opiates
Hallucinogens
Diagnostic Testing
Point-of-Care
Home
Each subsegment is discussed in detail, describing the drug, complications, diagnostic testing, therapeutic management, and current products on the market to treat abuse of the drug.
INFORMATION SOURCES
The information and analysis presented in this BCC Research report are based on extensive firsthand interviews with primary executives, product managers, and clinical specialists in the area of addiction and substance abuse. Background information was obtained from various government, business, medical journal, psychiatric journal and trade magazines; from statistics from the National Center on Drug Abuse; and from interviews with psychiatrists, psychologists, drug treatment counselors, and nurses. Key information from published literature was used to conduct interviews with industry participants to validate and obtain expert opinions on current and future trends. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as to formulate market projections.
All market data pertain to the U.S. market at the manufacturer’s level. Data are expressed in 2008 U.S. dollars. The base year was 2007. Historical data are provided for 2006 and forecast data are provided for 2008 and 2013. Historical, base year and forecast data are provided for each market segment and subsegment. Market shares are provided for each market segment for the 2007 base year.
Top of Page
Table of Contents
CHAPTER ONE: INTRODUCTION 1
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
INTENDED AUDIENCE 1
SCOPE OF REPORT 2
INFORMATION SOURCES 2
ANALYST CREDENTIALS 2
RELATED BCC REPORTS 2
BCC ONLINE SERVICES 3
DISCLAIMER 3
CHAPTER TWO: EXECUTIVE SUMMARY 4
SUMMARY TABLE US MARKET FOR ADDICTION AND SUBSTANCE ABUSE TREATMENTS AND DIAGNOSTICS, THROUGH 2013 ($ MILLIONS) 5
SUMMARY FIGURE US MARKET FOR ADDICTION AND SUBSTANCE ABUSE TREATMENTS AND DIAGNOSTICS, 2006-2013 ($ MILLIONS) 6
CHAPTER THREE: INDUSTRY OVERVIEW 7
HISTORY OF SUBSTANCE ABUSE 7
OVERVIEW OF SUBSTANCE ABUSE 8
OVERVIEW OF SUBSTANCE ABUSE (CONTINUED) 9
MODELS OF ADDICTION 10
ADDICTION THEORIES 11
Biological Theories 11
Psychological Theories 12
Sociocultural Theories 12
PATTERNS OF SUBSTANCE ABUSE 12
RISK FACTORS 13
ADDICTIVE PROCESS 13
DEMOGRAPHIC TRENDS 14
TABLE 1 US POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2005-2007 (MILLIONS) 14
FIGURE 1 US POPULATION BY SELECTED AGE GROUPS, 2006-2008 (MILLIONS) 15
TABLE 2 WORLDWIDE POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2005-2007 (MILLIONS) 15
FIGURE 2 WORLDWIDE POPULATION BY SELECTED AGE GROUPS, 2006-2008 (MILLIONS) 16
TOBACCO USE 16
FIGURE 3 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 12 OR OLDER BY TYPE OF TOBACCO USE, 2005 (MILLION PEOPLE) 17
Age 17
FIGURE 4 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 12 OR OLDER, 2005 (%) 18
Gender 18
FIGURE 5 PAST MONTH OF TOBACCO USE FOR MALES AND FEMALES AGED 12 OR OLDER, 2005 (%) 19
Race/Ethnicity 19
FIGURE 6 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 12 OR OLDER BY RACE/ETHNICITY, 2005 (%) 20
Education 20
FIGURE 7 PAST MONTH OF TOBACCO USE AMONG PERSONS AGED 18 OR OLDER BY EDUCATION LEVEL, ESTIMATED, 2006 (%) 21
College Students 21
FIGURE 8 PAST MONTH OF TOBACCO USE ENROLLMENT STATUS FOR COLLEGE STUDENTS AGED 18 TO 22, ESTIMATED, 2006 (%) 22
Employment 22
FIGURE 9 PAST MONTH OF TOBACCO BY EMPLOYMENT STATUS 18 AND OLDER, ESTIMATED, 2006 (%) 23
Geographic Area 23
FIGURE 10 PAST MONTH OF TOBACCO USE BY GEOGRAPHIC REGION BASED ON POPULATION DENSITY FOR AGES 12 OR OLDER, ESTIMATED, 2006 (%) 24
Association of Tobacco Use with Illicit Drug and Alcohol Use 24
FIGURE 11 PAST MONTH ILLICIT DRUG, ALCOHOL USE AMONG SMOKERS AND NONSMOKERS AGED 12 OR OLDER, ESTIMATED 2006 (%) 25
ALCOHOL USE 25
FIGURE 12 ALCOHOL CONSUMPTION AMONG ADULTS 18 YEARS OF AGE AND OVER, BY DRINKING STATUS: UNITED STATES, 1997 AND 2006 (%) 26
Alcohol Frequency 26
FIGURE 13 PAST MONTH ALCOHOL USE AMONG PERSONS AGED 12 OR OLDER BY FREQUENCY: UNITED STATES, 2002-2005 (%) 27
Age 27
FIGURE 14 PAST MONTH ALCOHOL USE AMONG PERSONS BY AGE, 2005 (%) 28
Gender 29
FIGURE 15 PAST MONTH ALCOHOL USE FOR MALES AND FEMALES AGE 12 OR OLDER, 2005 (%) 29
Pregnant Women 29
FIGURE 16 PAST MONTH OF ALCOHOL USE FOR PREGNANT AND NONPREGNANT WOMEN AGED 15-44, ESTIMATED 2002-2007 (%) 30
Race/Ethnicity 30
FIGURE 17 PAST MONTH ALCOHOL USE AMONG PERSONS AGED 12 OR OLDER BY RACE/ETHNICITY, 2005 (%) 31
Education 31
FIGURE 18 PAST MONTH ALCOHOL USE AMONG PERSONS AGED 18 OR OLDER BY EDUCATION LEVEL, ESTIMATED, 2005-2006 (%) 32
College Students 32
FIGURE 19 PAST MONTH ALCOHOL USE ENROLLMENT STATUS FOR COLLEGE STUDENTS AGED 18-22, ESTIMATED, 2002 AND 2006 (%) 33
Employment 33
FIGURE 20 PAST MONTH ALCOHOL USE BY EMPLOYMENT STATUS 18 AND OLDER, ESTIMATED, 2005-2006 (%) 34
Geographic Area 34
FIGURE 21 ALCOHOL CONSUMPTION AMONG ADULTS 18 YEARS OF AGE AND OVER, BY UNITED STATES GEOGRAPHIC REGION, 1997 AND 2006 (%) 35
Driving Under the Influence of Alcohol 35
FIGURE 22 PAST YEAR FREQUENCY OF DRIVING UNDER THE INFLUENCE OF ALCOHOL, AGES 12 OR OLDER, ESTIMATED, 2005 AND 2006 (%) 36
ILLICIT DRUG USE 36
FIGURE 23 PAST MONTH ILLICIT DRUG USE AMONG PERSONS AGED 12 OR OLDER BY TYPE OF DRUG: UNITED STATES, 2002-2005 (%) 37
FIGURE 23 (CONTINUED) 38
Age 38
FIGURE 24 PAST MONTH ILLICIT DRUG USE BY AGE, 2005 (%) 39
Gender 39
FIGURE 25 PAST MONTH ILLICIT DRUG USE FOR MALES AND FEMALES AGED 12 OR OLDER, 2005 (%) 40
Pregnant Women 40
FIGURE 26 PAST MONTH ILLICIT DRUG USE FOR PREGNANT AND NONPREGNANT WOMEN AGED 15-44, ESTIMATED, 2005-2006 (%) 41
Race/Ethnicity 41
FIGURE 27 PAST MONTH ILLICIT DRUG USE AMONG PERSONS AGED 12 OR OLDER BY RACE/ETHNICITY, ESTIMATED, 2005 42
Education 42
FIGURE 28 PAST MONTH ILLICIT DRUG USE AMONG PERSONS AGED 18 OR OLDER BY EDUCATION LEVEL, ESTIMATED, 2005-2006 43
College Students 43
FIGURE 29 PAST MONTH ILLICIT DRUG USE BY ENROLLMENT STATUS FOR COLLEGE STUDENTS AGED 18-22, ESTIMATED, 2005-2006 (%) 44
Employment 44
FIGURE 30 PAST MONTH ILLICIT DRUG USE BY EMPLOYMENT STATUS 18 AND OLDER, ESTIMATED, 2005-2006 (%) 45
Geographic Area 45
FIGURE 31 PAST MONTH ILLICIT DRUG USE FOR GEOGRAPHIC REGION BASED ON POPULATION DENSITY AGES 12 OR OLDER, ESTIMATED, 2005-2006 (%) 46
Criminal Justice Populations 46
FIGURE 32 PAST YEAR ILLICIT DRUG USE BY PAROLE AND PROBATION STATUS AGED 18 OR OLDER, ESTIMATED, 2005-2006 (%) 47
Frequency of Use 47
Association with Cigarette and Alcohol Use 47
FIGURE 33 PAST MONTH ALCOHOL AND TOBACCO USE AMONG ILLICIT DRUG USERS AND NON ILLICIT DRUG USERS AGED 12 OR OLDER, ESTIMATED, 2005–2006 48
Driving Under the Influence of Illicit Drugs 48
FIGURE 34 PAST YEAR FREQUENCY OF DRIVING UNDER THE INFLUENCE OF ILLICIT DRUGS, AGES 12 OR OLDER, ESTIMATED, 2005-2006 (MILLIONS) 49
ADDICTION TREATMENT COSTS SHIFTING 49
MANAGED CARE IMPACT 50
PARITY LAW 51
REIMBURSEMENT ISSUES 51
TABLE 3 FACILITY PAYMENT OPTIONS, BY FACILITY OPERATION AND PRIMARY FOCUS OF FACILITY, MARCH 31, 2006 (PERCENT DISTRIBUTION) 52
TABLE 4 FACILITY PAYMENT OPTIONS, BY FACILITY OPERATION AND PRIMARY FOCUS OF FACILITY: MARCH 31, 2006 (PERCENT DISTRIBUTION) 53
ECONOMIC COSTS OF SUBSTANCE ABUSE 53
TABLE 5 COMPARISON OF COSTS OF MAJOR HEALTH PROBLEMS IN US ($ BILLIONS) 54
TABLE 6 ECONOMIC COSTS TO SOCIETY OF DRUG ABUSE 1992-2002 ($ MILLIONS) 55
STUMBLING BLOCKS TO DRUG ABUSE TREATMENT 56
NEW AVENUES FOR TREATMENT OF SUBSTANCE ABUSE 56
TABLE 7 TOTAL ADMISSIONS TO TREATMENT FACILITIES BY PRIMARY SUBSTANCE AND STATE?ALCOHOL, COCAINE, MARIJUANA AND HEROIN 57
TABLE 7 (CONTINUED) 58
TABLE 8 TOTAL ADMISSIONS TO TREATMENT FACILITIES BY PRIMARY SUBSTANCE AND STATE?OTHER OPIATES, PCPS, HALUCINOGENS, AMPHETAMINES, OTHER STIMULANTS, AND TRANQUILIZERS 59
TABLE 8 (CONTINUED) 60
TABLE 9 TOTAL ADMISSIONS TO TREATMENT FACILITIES BY PRIMARY SUBSTANCE AND STATE?SEDATIVES, INHALANTS, AND OTHER 60
TABLE 9 (CONTINUED) 61
TABLE 10 USE OF SUBSTANCES BY AMONG PERSONS AGED 50 OR OLDER, ESTIMATED 1999 AND PROJECTED 2020 BY GENDER, RACE, AND AGE GROUP, 1999 62
TABLE 11 USE OF SUBSTANCES BY PERSONS AGED 50 OR OLDER, BY GENDER, RACE, AND AGE GROUP, 2020 63
REGULATORY ISSUES 64
EFFECTS OF POLY DRUG ABUSE 64
POLYDRUG USE BY AGE 64
TABLE 12 ADMISSIONS REPORTING POLYDRUG ABUSE, BY AGE GROUP, 2002 65
PRIMARY AND SECONDARY USE 65
THE UNINSURED 65
TABLE 13 TOP 10 PRINCIPAL DIAGNOSES IN US HOSPITALS WHICH HAVE UNINSURED RATES, 2002 66
TREATMENT FACILITIES AND PROGRAMS 66
OWNERSHIP OF SUBSTANCE ABUSE FACILITIES 67
TABLE 14 FACILITY OPERATION: NUMBER AND PERCENT DISTRIBUTION, 2002-2006 68
TREATMENT COSTS 68
TABLE 15 ESTIMATED TOTAL COSTS FOR SUBSTANCE ABUSE TREATMENT AND COST PER ADMISSION, BY TYPE OF CARE: 1997 (INFLATED TO 2002 COST LEVELS) 69
RESIDENTIAL REHABILITATION PATTERNS 69
Culture 69
Antabuse 70
Basic Methods 70
SELF-HELP GROUPS 71
TABLE 16 PERCENT DISTRIBUTION OF PERSONS AGED 12 OR OLDER WHO ATTENDED A ?SELF-HELP? GROUP IN THE PAST YEAR BECAUSE OF THEIR ALCOHOL OR ILLICIT DRUG USE AND OF TOTAL POPULATION AGED 12 & OLDER, BY SOCIODEMOGRAPHIC CHARACTERISTICS: 2006 AND 2007 71
TABLE 16 (CONTINUED) 72
FIGURE 35 PERCENTAGES OF PAST YEAR SELF-HELP GROUP ATTENDEES AGED 12 OR OLDER, BY SUBSTANCE(S) FOR WHICH THEY ATTENDED A ?SELF-HELP? GROUP, 2006 AND 2007 (%) 72
FIGURE 35 (CONTINUED) 73
NATIONAL PROGRAMS FOR SUBSTANCE ABUSE 73
BARRIERS TO MARKET ENTRY 74
NONACCEPTANCE OF MEDICAL MODELS OF ADDICTION 75
CHAPTER FOUR: PHARMACEUTICAL PRODUCTS 76
STIMULANTS 76
NICOTINE 76
Characteristics 76
Effects of Use 77
Complications 77
Therapeutic Management 78
TABLE 17 SMOKING CESSATION PRODUCTS 78
Therapeutic Management (Continued) 79
AMPHETAMINES 80
Characteristics 80
Effects of Use 81
Complications 81
Therapeutic Management 82
TABLE 18 AMPHETAMINE ABUSE TREATMENTS 82
COCAINE AND CRACK 82
Characteristics 82
Effects of Use 83
Complications 83
Therapeutic Management 84
TABLE 19 COCAINE ABUSE TREATMENTS 85
OTHER STIMULANTS 85
DEPRESSANTS 86
SEDATIVES-HYPNOTICS 87
Characteristics 87
Effects of Use 87
Complications 88
Therapeutic Management 88
ALCOHOL 88
Characteristics 88
Effects of Use 89
Complications 89
Complications (Continued) 90
Therapeutic Management 91
TABLE 20 ALCOHOL ABUSE TREATMENTS 92
OPIATES 92
Characteristics 92
Effects of Use 93
Complications 94
Therapeutic Management 94
Methadone 95
Other Products 95
Other Products (Continued) 96
TABLE 21 OPIATE ABUSE TREATMENTS 97
HALLUCINOGENS 97
CANNABIS 98
Characteristics 98
Effects of Use 98
Complications 99
Therapeutic Management 99
LYSERGIC ACID DIETHYLAMIDE, DIMETHYLTRYPTAMINE, MESCALINE, AND RELATED SUBSTANCES 99
Characteristics 99
Characteristics (Continued) 100
Effects of Use 101
Therapeutic Management 102
OTHER HALLUCINOGENS 102
INHALANTS AND OTHER DRUGS OF ABUSE 103
Gases, Solvents and Nitrites 103
Gases, Solvents ? (Continued) 104
Anabolic Steroids 105
DIAGNOSTIC TESTING 106
URINE TESTING 106
SALIVA TESTING 107
BLOOD TESTING 107
PATCH TESTING 107
HAIR TESTING 108
SAMHSA POSITIVE DRUG TEST GUIDELINES 108
TABLE 22 POSITIVE DRUG TEST GUIDELINES (NG/ML) 109
DRUG TESTING INDEXES 109
TABLE 23 ANNUAL POSITIVITY RATES FOR US WORKERS, BY YEAR 1988-2004 (%) 110
TABLE 24 POSITIVITY RATES FOR US WORKERS BY TESTING REASON, 2000-2004 110
TABLE 25 POSITIVITY RATES FOR US WORKERS BY DRUG CATEGORY AS A PERCENTAGE OF ALL POSITIVE TESTS (%) 110
TABLE 25 (CONTINUED) 111
POINT-OF-CARE SUBSTANCE ABUSE DIAGNOSTIC TESTING 111
Tobacco Testing 111
TABLE 26 POINT-OF-CARE NICOTINE DIAGNOSTIC TEST PRODUCTS 112
Jant Pharmacal 112
Nymox Pharmaceuticals 112
Princeton BioMeditech Corporation 112
Alcohol Testing 113
TABLE 27 POINT OF CARE ALCOHOL DIAGNOSTIC TEST PRODUCTS 113
Jant Pharmacal 113
MEDTOX Scientific, Inc 113
OraSure Technologies 113
Princeton BioMeditech Corporation 114
Varian, Inc 114
Drug Testing 114
TABLE 28 POINT-OF-CARE DRUG DIAGNOSTIC TESTING PRODUCTS 114
Alfa Scientific Designs 115
American Bio Medica 115
BioScan Screening Systems 115
Biosite Diagnostics 115
Inverness Medical 116
MEDTOX Scientific, Inc 116
OraSure Technologies 116
Phamatech 116
Princeton BioMeditech 117
Psychemedics Corp 117
Varian, Inc 117
Sun Biomedical 118
HOME SUBSTANCE ABUSE DIAGNOSTIC TESTING 118
Alcohol Testing 118
TABLE 29 ALCOHOL HOME DIAGNOSTIC TESTING PRODUCTS 118
Jant Pharmacal 119
Sun Biomedical Laboratories 119
Drug Testing 119
TABLE 30 DRUG HOME DIAGNOSTIC TESTING PRODUCTS 119
Psychemedics 119
Dr Brown’s (Elan Corporation) 119
Inverness Medical Innovations, Inc 120
Phamatech 120
Princeton BioMeditech 120
Psychemedics 120
Sun Biomedical Laboratories 120
Sun Biomedical ? (Continued) 121
CHAPTER FIVE: MARKET SIZE AND GROWTH 122
MARKET SIZE AND GROWTH 122
TABLE 31 US MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE TREATMENTS AND DIAGNOSTICS, THROUGH 2013 ($ MILLIONS) 123
FIGURE 36 US MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE TREATMENTS AND DIAGNOSTICS, 2006-2013 ($ MILLIONS) 123
PRESCRIPTION AND OVER-THE-COUNTER PHARMACEUTICAL TREATMENTS 123
SMOKING CESSATION 123
DRUG AND ALCOHOL ABUSE 124
TABLE 32 US MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS BY TREATMENT TYPE, THROUGH 2013 ($ MILLIONS) 124
FIGURE 37 US MARKET SIZE OF ADDICTION AND SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS BY TREATMENT TYPE, THROUGH 2013 ($ MILLIONS) 124
DIAGNOSTIC TESTING 125
POINT-OF-CARE TESTING 125
HOME TESTING 125
TABLE 33 US MARKET SIZE OF SUBSTANCE ABUSE DIAGNOSTICS, THROUGH 2013 ($ MILLIONS) 125
FIGURE 38 US MARKET SIZE OF SUBSTANCE ABUSE DIAGNOSTICS, 2006-2013 ($ MILLIONS) 126
CHAPTER SIX: RESEARCH AND DEVELOPMENT 127
GOALS 127
AREAS OF CONCENTRATION 127
INDUSTRY NEEDS 128
CURRENT DRUGS IN CLINICAL TRIALS 129
ALCOHOL TREATMENT 129
OPIATE TREATMENT 129
GENERAL ADDICTION 130
TOBACCO TREATMENT 130
TABLE 34 SUBSTANCE ABUSE PRODUCTS IN DEVELOPMENT 131
TABLE 34 (CONTINUED) 132
MISCELLANEOUS SUBSTANCE ABUSE TREATMENT DISCOVERIES 132
MISCELLANEOUS SUBSTANCE ABUSE ?(CONTINUED) 133
MISCELLANEOUS SUBSTANCE ABUSE ?(CONTINUED) 134
CHAPTER SEVEN: INDUSTRY STRUCTURE 135
MARKET LEADERS 135
PFIZER 135
RECKITT BENCKISER 135
GLAXOSMITHKLINE 135
NOVARTIS 135
PSYCHEMEDICS 136
ORASURE TECHNOLOGIES 136
TABLE 35 TOTAL MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS, 2007 136
FIGURE 39 TOTAL MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE PHARMACEUTICAL TREATMENTS, 2007 (%) 137
TABLE 36 US MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE DIAGNOSTICS, 2007 137
FIGURE 40 US MANUFACTURERS MARKET SHARE OF SUBSTANCE ABUSE DIAGNOSTICS, 2007 (%) 138
INDUSTRY PARTICIPANTS BY PRODUCT TYPE 138
TABLE 37 LEADING SUBSTANCE ABUSE PHARMACEUTICAL TREATMENT AND DIAGNOSTIC TESTING MANUFACTURERS BY PRODUCT TYPE, 2008 138
TABLE 37 (CONTINUED) 139
MARKET ANALYSIS 139
Anti-Depressant Market 139
Additional Therapies 140
Opportunities 140
Opportunities (Continued) 141
CHAPTER EIGHT: COMPANY PROFILES 142
GLAXOSMITHKLINE PLC 142
HISTORY 142
NOVARTIS PHARMACEUTICALS CORP 142
HISTORY 143
ORASURE TECHNOLOGIES 143
HISTORY 143
PFIZER, INC 143
HISTORY 144
PHAMATECH, INC 144
HISTORY 144
PSYCHEMEDICS CORP 144
HISTORY 145
RECKITT BENCKISER PLC 145
HISTORY 145
APPENDIX A?LIST OF COMPANIES 146
ABBOT DIAGNOSTICS 146
ABBOTT LABORATORIES 146
ALFA SCIENTIFIC DESIGNS, INC 146
ALKERMES, INC 146
AMERICAN BIO MEDICA CORPORATION 146
ARADIGM CORPORATION 147
BARR LABORATORIES, INC 147
BIOSCAN SCREENING SYSTEMS, INC 147
BIOSITE, INC 147
BIOVAIL CORPORATION 147
BRISTOL-MYERS SQUIBB COMPANY 148
CARY PHARMACEUTICALS, INC 148
CELTIC PHARMA MANAGEEMNT LP 148
CEPHALON, INC 148
CYTOS BIOTECHNOLOGY AG 148
DRUG ENFORCEMENT ADMINISTRATION 149
ELAN CORPORATION, PLC 149
ELBION NV 149
ELI LILLY & COMPANY 149
ENDO PHARMACEUTICALS 149
FOOD AND DRUG ADMINISTRATION 150
FOREST LABORATORIES, INC 150
GLAXOSMITHKLINE PLC 150
INVERNESS MEDICAL INNOVATIONS, INC 150
JANT PHARMACAL CORPORATION 150
JOHNSON & JOHNSON 151
JOINT COMMISSION ON ACCREDITATION OF HEALTHCARE ORGANIZATIONS (JCAHO) 151
MALLINCKRODT 151
MEDTOX SCIENTIFIC, INC 151
NABI BIOPHARMACEUTICALS 151
NATIONAL INSTITUTE ON ALCOHOL ABUSE & ALCOHOLISM 152
NATIONAL INSTITUTE ON DRUG ABUSE 152
NOVARTIS INTERNATIONAL AG 152
NOVARTIS PHARMACEUTICALS CORP 152
NYMOX PHARMACEUTICAL CORP 152
OFFICE OF NATIONAL DRUG CONTROL POLICY 153
ORASURE TECHNOLOGIES, INC 153
OVATION PHARMACEUTICALS, INC 153
PFIZER, INC 153
PHAMATECH, INC 153
PLIVA, INC 154
PRINCETON BIOMEDITECH CORP 154
PSYCHEMEDICS CORPORATION 154
PURDUE PHARMA, LP 154
RECKITT-BENCKISER PLC 154
ROCHE 155
SANOFI-AVENTIS 155
SOMAXONE PHARMACEUTICALS, INC 155
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION (SAMHSA) 155
SUN BIOMEDICAL LABORATORIES, INC 155
TITAN PHARMACEUTICALS, INC 156
US DEPARTMENT OF HEALTH AND HUMAN SERVICES 156
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO 156
VALEANT PHARMACEUTICALS INTERNATIONAL 156
VARIAN, INC 156
XANODYNE PHARMACEUTICALS, INC 157
APPENDIX B?LIST OF SUBSTANCE ABUSE TREATMENT FACILITIES 158
TABLE 38 LIST OF SUBSTANCE ABUSE TREATMENT FACILITIES 158
TABLE 38 (CONTINUED) 159
TABLE 38 (CONTINUED) 160
TABLE 38 (CONTINUED) 161
TABLE 38 (CONTINUED) 162
TABLE 38 (CONTINUED) 163
TABLE 38 (CONTINUED) 164
TABLE 38 (CONTINUED) 165
TABLE 38 (CONTINUED) 166
TABLE 38 (CONTINUED) 167
TABLE 38 (CONTINUED) 168
TABLE 38 (CONTINUED) 169
TABLE 38 (CONTINUED) 170
TABLE 38 (CONTINUED) 171
TABLE 38 (CONTINUED) 172
TABLE 38 (CONTINUED) 173
TABLE 38 (CONTINUED) 174
TABLE 38 (CONTINUED) 175
TABLE 38 (CONTINUED) 176
TABLE 38 (CONTINUED) 177
TABLE 38 (CONTINUED) 178
TABLE 38 (CONTINUED) 179
TABLE 38 (CONTINUED) 180
TABLE 38 (CONTINUED) 181
TABLE 38 (CONTINUED) 182
TABLE 38 (CONTINUED) 183
TABLE 38 (CONTINUED) 184
TABLE 38 (CONTINUED) 185
TABLE 38 (CONTINUED) 186
TABLE 38 (CONTINUED) 187
TABLE 83 (CONTINUED) 188
TABLE 38 (CONTINUED) 189
TABLE 38 (CONTINUED) 190
TABLE 83 (CONTINUED) 191
TABLE 83 (CONTINUED) 192
TABLE 83 (CONTINUED) 193
TABLE 83 (CONTINUED) 194
TABLE 83 (CONTINUED) 195
TABLE 83 (CONTINUED) 196
TABLE 83 (CONTINUED) 197
For full details, please email keithw@cmsinfo.com
Top of Page
Buy now!
Top of Page
|
|
